Browsing by Author "Lynn Morris"

Filter results by typing the first few letters
Now showing 1 - 4 of 4
  • Thumbnail Image
    Item
    High monoclonal neutralization titers reduced breakthrough HIV1 viral loads in the Antibody Mediated Prevention trials
    (NATURE PUBLISHING GROUP) D.B Reeves; B.T Mayer; A deCamp; Y Huang; Lynn Morris; Nonhlanhla Mkhize; E et al
  • Thumbnail Image
    Item
    HIV1 resupression on a firstline regimen despite the prescence of phenotypic drug resistance
    Adriaan Basson; Salome Charalambous; Christopher Hoffmann; Lynn Morris
  • Thumbnail Image
    Item
    HIV1 resupression on a firstline regimen despite the prescence of phenotypic drug resistance
    (Public Library of Science) Adriaan Basson; Salome Charalambous; Christopher Hoffmann; Lynn Morris
    We have previously reported on HIV-1 infected patients who fail anti-retroviral therapy but manage to re-suppress without a regimen change despite harbouring major drug resistance mutations. Here we explore phenotypic drug resistance in such patients in order to better understand this phenomenon. Patients (n = 71) failing a non-nucleoside reverse transcriptase inhibitor (NNRTI)-based regimen, but who subsequently re-suppressed on the same regimen, were assessed for HIV-1 genotypic drug resistance through Sanger sequencing. A subset (n =23) of these samples, as well as genotypically matched samples from patients who did not re-suppress (n = 19), were further assessed for phenotypic drug resistance in an in vitro single cycle assay. Half of the patients (n = 36/71, 51%) harboured genotypic drug resistance, with M184V(n=18/36,50%)andK103N(n=16/36,44%)being the most prevalent mutations. No significant difference in the median time to re-suppression (31–39 weeks) were observed for either group (p = 0.41). However, re-suppressors with mutant virus rebounded significantly earlier than those with wild-type virus (16 vs. 33 weeks; p = 0.014). Similar phenotypic drug resistance profiles were observed between patients who re-suppressed and patients who failed to re-suppress. While most remained susceptible to stavudine (d4T) and zidovudine (AZT), both groups showed a reduced susceptibility to 3TC and NNRTIs. HIV- 1 infected patients on an NNRTI-based regimen can achieve viral re-suppression on the same regimen despite harbouring viruses with genotypic and phenotypic drug resistance. However, re-suppression was less durable in those with resistance, reinforcing the importance of appropriate regimen choices, ongoing viral load monitoring and adherence counselling.
  • Thumbnail Image
    Item
    SARSCoV2 501YV2 escapes neutralization by South African COVID19 donor plasma
    Constantinos Wibmer; Frances Ayres; Tandile Hermanus; Mashudu Madzivhandila; E et al; Bronwen Lambson; Anne Von Gottberg; Cheryl Cohen; Lynn Morris; Jinal Bhiman; Penelope Moore